Skip to content
OpenCapital
Get started

Metagenomi Therapeutics, Inc. MGX Q2 2025 earnings

Reported August 12, 2025 · Before market open

Revenue$8.5MBeat by $573.0K
EPS-$0.54Beat by $0.14
Revenue estimate$7.9M
EPS estimate-$0.68

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$3.0M
EPS estimate-$0.55

Versus estimates

Revenue

Q1 2026$1.2MMiss by $4.7MQ4 2025$3.9MMiss by $3.4MQ3 2025$8.7MBeat by $836.4K
Q2 2025$8.5MBeat by $573.0K
Q1 2025$4.1MMiss by $4.2MQ4 2024$9.6MBeat by $382.7K

Diluted EPS

Q1 2026-$0.61Miss by $0.01Q4 2025-$0.60Miss by $0.02Q3 2025-$0.55Beat by $0.05
Q2 2025-$0.54Beat by $0.14
Q1 2025-$0.68Miss by $0.06Q4 2024-$0.63Miss by $0.01

Ask the moment Metagenomi Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Metagenomi Therapeutics, Inc. report Q2 2025 earnings?
Metagenomi Therapeutics, Inc. (MGX) reported Q2 2025 earnings on August 12, 2025 before market open.
What were Metagenomi Therapeutics, Inc. 's Q2 2025 revenue and EPS?
Metagenomi Therapeutics, Inc. reported revenue of $8.5M and eps of $-0.54 for Q2 2025.
Did Metagenomi Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $7.9M by $573.0K. EPS beat the consensus estimate of $-0.68 by $0.14.
How did Metagenomi Therapeutics, Inc. 's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 57.5% from $20.0M a year earlier and eps declined 86.2% from $-0.29.
Where can I find Metagenomi Therapeutics, Inc. 's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-107308) directly on SEC EDGAR. The filing index links above go to sec.gov.